Welcome to our dedicated page for Si-Bone SEC filings (Ticker: SIBN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SI-BONE, Inc. (NASDAQ: SIBN) files a range of reports with the U.S. Securities and Exchange Commission that provide detailed insight into its sacropelvic-focused medical device business. This SEC filings page brings together those documents and pairs them with AI-powered summaries to help interpret the information that matters for SIBN stock.
Through annual reports on Form 10-K and quarterly reports on Form 10-Q, SI-BONE discloses its revenue from sacroiliac joint fusion and related sacropelvic procedures, gross margin, operating expenses, net loss, adjusted EBITDA, cash and investments, and other key financial metrics. These filings also describe risk factors, clinical evidence supporting its technologies, and considerations related to reimbursement, supply chain, and the healthcare operating environment.
Current reports on Form 8-K are used by SI-BONE to announce material events such as quarterly financial results, preliminary unaudited revenue and cash figures, and leadership or board changes. For example, recent 8-K filings have referenced press releases on quarterly results, preliminary full-year revenue, and executive transitions, as well as consulting and retirement agreements with senior leaders and directors.
This page also provides access to other SEC documents that may include registration statements and proxy materials, which can address topics such as equity compensation, board composition, and corporate governance. For investors interested in insider activity, Forms 3, 4, and 5 (when filed) detail transactions by directors and officers in SIBN shares.
AI-generated highlights on this platform are designed to make SI-BONE’s filings easier to navigate by surfacing key figures, summarizing management’s discussion of performance, and pointing to sections that discuss sacropelvic technologies, clinical evidence, and reimbursement dynamics. Real-time updates from EDGAR ensure that new 10-K, 10-Q, and 8-K filings for SI-BONE, Inc. are available promptly, while AI summaries help reduce the time required to understand their implications.
SI-BONE, Inc. (SIBN) reported an insider transaction by its Senior Vice President, Operations & Administration and Chief Legal Officer on 11/17/2025. The executive sold 1,478 and 1,850 shares of common stock in two separate trades, coded as sales.
According to the disclosure, these sales were made solely to cover tax withholding obligations arising from the vesting of restricted stock units under a "sell to cover" arrangement and are described as non-discretionary trades. After the transactions, the reporting person beneficially owned 251,896 shares of common stock, including 125,823 shares issuable upon settlement of restricted stock units, each unit representing a right to receive one share.
SI-BONE, Inc. insider trading report: The Chief Financial Officer of SI-BONE, Inc. (SIBN) reported two sales of common stock on 11/17/2025 totaling 3,460 shares. One sale covered 1,275 shares at a weighted average price of $17.4098, and another covered 2,185 shares at a weighted average price of $17.4369. According to the disclosure, these transactions were "sell to cover" sales required to satisfy tax withholding obligations related to vesting restricted stock units and were not discretionary trades. After these transactions, the reporting person beneficially owned 205,073 shares of common stock, including 143,116 shares issuable upon settlement of restricted stock units.
SI-BONE, Inc. (SIBN)11/17/2025, she sold several small blocks of common stock, including 2,028 shares at a weighted average price of $17.4401, 2,231 shares at $17.4449, 3,197 shares at $17.4341, and 3,885 shares at $17.3996.
The filing explains that these sales were required to cover tax withholding obligations tied to the vesting of restricted stock units and were executed as "sell to cover" transactions rather than discretionary trades. On 11/18/2025, 5,411 additional shares were sold at a weighted average price of $17.6978 under a Rule 10b5-1 trading plan dated December 13, 2024.
After these transactions, Francis beneficially owned 408,363 shares directly, including 373,980 shares issuable upon settlement of restricted stock units, and 351,319 shares indirectly through a trust.
SI-BONE (SIBN) reported an insider transaction by CEO and Director Laura A. Francis. She sold 5,411 shares of common stock on 11/11/2025 at a weighted‑average price of $17.0591, effected under a Rule 10b5-1 trading plan dated December 13, 2024.
After the sale, 356,730 shares were held indirectly by a trust, and 419,704 shares were held directly. The direct figure includes 396,297 shares issuable upon settlement of restricted stock units.
SI-BONE (SIBN) director Jeffrey W. Dunn reported option exercises and related sales on 11/11/2025. He exercised stock options at $4.32 for 23,148 shares and 56,852 shares, then sold the same amounts at $18.95 per share pursuant to a Rule 10b5-1 trading plan dated May 7, 2025.
Following these transactions, he directly held 10,307 shares. He also had indirect ownership of 118,874 shares held by The Jeffrey W. Dunn Living Trust. The direct total includes 10,307 shares issuable upon settlement of restricted stock units, each representing one share of common stock. The option awards referenced vest in equal monthly installments over four years, subject to continued service.
SI-BONE (SIBN)
SI-BONE (SIBN) reported Q3 2025 results with strong top-line growth and improved profitability trends. Revenue was $48,656,000, up 20.6% from $40,340,000, driven largely by higher U.S. case volumes. Gross margin expanded to 79.8% from 79.1%, lifting gross profit to $38,846,000.
Operating expenses rose to $44,229,000, primarily from higher sales and marketing and general and administrative costs, resulting in a smaller operating loss of $5,383,000 versus $7,633,000 a year ago. Net loss narrowed to $4,566,000 compared with $6,575,000, and net loss per share improved to $0.11 from $0.16.
Liquidity remained solid with cash and cash equivalents of $26,487,000 and short-term investments of $119,257,000. Inventory increased to $35,727,000 to support demand. Long-term borrowings were $35,540,000. Shares outstanding were 43,391,254 as of November 4, 2025.
SI-BONE, Inc. (SIBN) announced board and governance updates. Director Daniel Wolf resigned from the Board on November 6, 2025, and the company stated his resignation was not due to any disagreement with the company or management. Following his departure, the Board size was reduced from nine to eight, and current director Thomas A. West was appointed to the Audit Committee.
SI-BONE and Mr. Wolf entered into a 12-month consulting agreement covering marketing, strategy, business development and other corporate matters. The agreement accelerates vesting of 8,675 restricted stock units granted to Mr. Wolf on June 5, 2025, making them fully vested as of November 6, 2025, and provides cash compensation at an hourly rate set in applicable statements of work. The company also furnished a press release announcing results for the quarter ended September 30, 2025 as Exhibit 99.1.
SI‑BONE (SIBN) director reported a routine insider transaction. On 11/03/2025, the reporting person sold 293 shares of common stock at a weighted average price of $14.8038. The filing states this was a sell‑to‑cover to satisfy tax withholding from vesting RSUs, not a discretionary trade.
Following the transaction, the filer beneficially owns 10,831 shares directly and 118,350 shares indirectly via a trust. The direct holdings include 10,307 shares issuable upon settlement of restricted stock units, each representing one share.
SI-BONE, Inc. (SIBN) reported insider sales by Michael A. Pisetsky, SVP, Ops & Adm/Chief Legal Officer, on 10/02/2025. The Form 4 shows a total of 3,128 shares of common stock sold across multiple trades to satisfy tax withholding on vesting restricted stock units; these sales are described as a "sell to cover" and not discretionary. Reported weighted average prices per transaction are $14.255, $14.1053, and $14.2537, and the filing lists 256,556, 256,522, and 255,224 shares beneficially owned after each reported sale line. The filing also discloses 132,362 shares issuable on settlement of restricted stock units retained by the reporting person.